KOD Stock Analysis: Kodiak Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.412m USD | 12M Return: 932.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.2M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing therapeutics for retinal diseases. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer being evaluated across multiple Phase 3 and Phase 2/3 studies targeting high-prevalence retinal conditions including wet age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and diabetic macular edema. The companys earlier-stage pipeline includes KSI-501, a bispecific antibody biopolymer conjugate targeting IL-6 and VEGF, and KSI-101, a bispecific protein developed for patients with retinal fluid and inflammation. Originally incorporated in 2009 as Oligasis, LLC, the company rebranded to Kodiak Sciences in September 2015 and went public in October 2018.
As a clinical-stage biotechnology company, Kodiak does not yet have approved products generating commercial revenue, and its value is largely tied to the progression of its clinical pipeline rather than current sales. The retinal disease market it targets is substantial and growing, driven by aging populations and the rising prevalence of conditions such as AMD and diabetic eye disease, making it a key focus area within the ophthalmology biopharmaceutical sector.
- Phase 3 tarcocimab failure clouds regulatory approval prospects
- Competition from Eylea HD and Vabysmo pressures market share
- Cash runway tightens as pipeline burn rate accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -11.45 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -146.9m > Net Income -230.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.9m) vs 12m ago 17.28% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 8.95%; Δ -8.95% > 0%) |
| Interest Coverage Ratio: -61.27 > 6 (EBIT TTM -227.0m / Interest Expense TTM 3.70m) |
| A: 0.41 (Total Current Assets 175.3m - Total Current Liabilities 49.6m) / Total Assets 306.0m |
| B: -5.28 (Retained Earnings -1.62b / Total Assets 306.0m) |
| C: -0.75 (EBIT TTM -227.0m / Avg Total Assets 302.0m) |
| D: 0.58 (Book Value of Equity 112.1m / Total Liabilities 193.9m) |
| Altman-Z'' = -18.97 = D |
As of July 08, 2026, the stock is trading at USD 38.30 with a total of 565,577 shares traded. Over the past week, the price has changed by +1.48%, over one month by +29.35%, over three months by -8.35% and over the past year by +932.35%.
Current recommended Stop Loss: 34.90 (which is 8.9% or 1.2 ATR below the current price).
Kodiak Sciences has received a consensus analysts rating of 2.83. Therefore, it is recommended to hold KOD.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 3
- StrongSell: 0
| Analysts Target Price | 62.7 | 63.6% |
P/B = 21.5143
Revenue TTM = 0.0 USD
EBIT TTM = -227.0m USD
EBITDA TTM = -201.0m USD
Long Term Debt = 144.3m USD (estimated: total debt 156.0m - short term 11.7m)
Short Term Debt = 11.7m USD (from shortTermDebt, last quarter)
Debt = 212.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 56.0m
Net Debt = 42.5m USD (calculated: Debt 212.0m - CCE 169.5m)
Enterprise Value = 2.45b USD (2.41b + Debt 212.0m - CCE 169.5m)
Interest Coverage Ratio = -61.27 (Ebit TTM -227.0m / Interest Expense TTM 3.70m)
EV/FCF = -16.96x (Enterprise Value 2.45b / FCF TTM -144.7m)
FCF Yield = -5.90% (FCF TTM -144.7m / Enterprise Value 2.45b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM -388k) / Revenue TTM)
Tobins Q-Ratio = 8.02 (Enterprise Value 2.45b / Total Assets 306.0m)
Interest Expense / Debt = 1.75% (Interest Expense 3.70m / Debt 212.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -179.3m (EBIT -227.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.88 (Total Current Assets 175.3m / Total Current Liabilities 60.9m)
Debt / Equity = 1.89 (Debt 212.0m / totalStockholderEquity, last quarter 112.1m)
Debt / EBITDA = -0.21 (negative EBITDA) (Net Debt 42.5m / EBITDA -201.0m)
Debt / FCF = -0.29 (negative FCF - burning cash) (Net Debt 42.5m / FCF TTM -144.7m)
Total Stockholder Equity = 90.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -76.39% (Net Income -230.7m / Total Assets 306.0m)
RoE = -253.8% (Net Income TTM -230.7m / Total Stockholder Equity 90.9m)
RoCE = -96.50% (EBIT -227.0m / Capital Employed (Equity 90.9m + L.T.Debt 144.3m))
RoIC = -66.88% (negative operating profit) (NOPAT -179.3m / Invested Capital 268.1m)
WACC = 12.80% (E(2.41b)/V(2.62b) * Re(13.80%) + D(212.0m)/V(2.62b) * Rd(1.75%) * (1-Tc(0.21)))
Discount Rate = 13.80% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 7.58%
[DCF] Fair Price = unknown (Cash Flow -144.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.48 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.96 | Chg30d=+6.96% | Revisions=+57% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.93 | Chg30d=+7.95% | Revisions=+57% | Analysts=6
EPS current Year (2026-12-31): EPS=-3.74 | Chg30d=+7.78% | Revisions=+57% | GrowthEPS=+13.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.12 | Chg30d=+8.76% | Revisions=+57% | GrowthEPS=+16.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +84% (up=16, down=0)